AT&T’s Financial Results Top Estimates On Strong Subscriber Additions
AT&T (T) posted better-than-expected financial results for the fourth quarter of 2024 as its subscriber numbers rose to end the year.The Dallas, Texas-based telecommunications company reported earnings per share (EPS) of $0.54 U.S., which beat the $0.50 U.S. consensus forecast on Wall Street. Revenue in the quarter totaled $32.30 billion U.S., which was slightly ahead of the $32 billion U.S. expected among analysts. AT&T attributed the decent results to gains in its fifth generation (5G) wireless and fibre optic internet subscribers. Management said they added 482,000 net new mobile phone customers and 307,000 fibre internet customers during Q4 2024, with both figures coming in above analyst forecasts. Mobile phone service revenue increased 3.3% from a year ago to $16.60 billion U.S., and consumer broadband revenue rose 7.8% from a year ago to $2.90 billion U.S.AT&T’s full-year earnings per share of $2.26 U.S. also topped the guidance of $2.20 U.S. to $2.25 U.S. a share it had issued at an investor day event last December.In terms of forward guidance, AT&T said it expects earnings per share of $1.97 U.S. to $2.07 U.S. for all of 2025. The company added that it still expects to complete the sale of its 70% stake in the digital satellite service to private-equity investor TPG (TPG) in mid-2025.The stock of AT&T has gained 32% over the last 12 months to trade at $22.72 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


